Key result
Perindopril-based therapy reduced major vascular events in patients with prior stroke (HR 0.74; 95% CI 0.66-0.84), with consistent relative benefits across all BMI categories.
Why the study?
Does perindopril-based blood pressure-lowering therapy reduce major vascular events in participants with cerebrovascular disease across different body mass index categories?
Population
6105 participants with cerebrovascular disease
Comparison
Perindopril-based blood pressure-lowering therapy vs Placebo
Design
RCT, randomized
Follow-up
5 years
Authors
Loading...
Supports perindopril-based BP lowering post-stroke across BMI; confirms consistent relative benefits with greater absolute gains in obesity.
RCT (n=6,105)
randomized
Does perindopril-based blood pressure-lowering therapy reduce major vascular events in participants with cerebrovascular disease across different body mass index categories?
Hazard Ratio: 0.74 (95% CI 0.66–0.84)
Blood pressure-lowering therapy provides consistent relative risk reduction for vascular events across all BMI categories, with greater absolute benefit in obese patients due to higher baseline risk.
Czernichow et al. (2010) conducted an RCT in Cerebrovascular disease (n=6,105). Perindopril-based blood pressure-lowering therapy vs. Placebo was evaluated on Major vascular events (HR 0.74, 95% CI 0.66-0.84). Perindopril-based therapy reduced major vascular events in patients with prior stroke (HR 0.74; 95% CI 0.66-0.84), with consistent relative benefits across all BMI categories.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: